Editorial Standards
How we source, write, review, correct, and update ketamine therapy content for patients.
Sourcing policy
Clinical claims (efficacy, safety, dosing, interactions, eligibility) are sourced from peer-reviewed publications indexed in PubMed or PMC, FDA labeling and REMS documentation, and published clinical practice guidelines. Secondary reporting (news articles, manufacturer blogs) is used only when it cites a verifiable primary source. We avoid citing other patient-education sites as primary sources for clinical claims.
Evidence-informed language
We describe our content as evidence-informed rather than evidence-based. Off-label ketamine use spans an evidence base that is meaningful but still maturing. We mark uncertainty with phrases such as 'available evidence suggests,' 'data is preliminary,' or 'this is contested' rather than presenting contested claims as settled.
Clinical review
Articles touching clinical decision-making are reviewed by a credentialed consulting clinician before publish. Reviewers are matched to subject area: an MD psychiatrist reviews mood-disorder and clinic-protocol content; a PharmD reviews dosing and formulation content; an LCSW reviews integration and support-system content. Reviewers may flag claims for revision, additional citation, or removal, and may decline to review subject matter outside their competence.
Conflict-of-interest disclosure
Ketamine Path may earn revenue from display advertising and from clearly-labeled provider directory listings. Editorial coverage is not sold. Advertisers do not preview, approve, or influence article content, and advertiser status does not affect inclusion in editorial roundups or comparison articles. Affiliate links, when present, are disclosed at the point of placement.
AI policy
We use AI assistance for drafting, outlining, and editorial workflow. Every published article — including AI-assisted drafts — is reviewed by a human editor for accuracy, sourcing, and tone, and clinical articles go through the clinical-review step described above. AI is not used to fabricate citations, statistics, or quotes; any factual claim must trace to a verifiable source in our research notes.
Review cadence and freshness
Each article displays a last-reviewed date. Articles are re-reviewed at least every 18 months. We trigger out-of-cycle reviews when the FDA issues new actions or labeling changes affecting ketamine or esketamine, when major clinical practice guidelines update, or when a significant peer-reviewed study challenges a current claim.
Corrections policy
Substantive corrections (any change to a clinical claim, statistic, or attribution) are appended to the affected article with a dated correction note. Minor edits (typos, formatting) are made silently. Correction requests can be sent via the contact page and are reviewed within 5 business days.
What we do not do
- We do not provide individual medical advice or respond to clinical questions about a specific person's case.
- We do not recommend specific dose ranges for at-home use outside of what licensed prescribers have published in clinical literature.
- We do not accept payments to suppress, soften, or expedite editorial coverage.
- We do not present preliminary or single-study findings as established practice.
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.